JP7692366B2 - メチルナルトレキソンの液体経口投与製剤 - Google Patents

メチルナルトレキソンの液体経口投与製剤 Download PDF

Info

Publication number
JP7692366B2
JP7692366B2 JP2021565869A JP2021565869A JP7692366B2 JP 7692366 B2 JP7692366 B2 JP 7692366B2 JP 2021565869 A JP2021565869 A JP 2021565869A JP 2021565869 A JP2021565869 A JP 2021565869A JP 7692366 B2 JP7692366 B2 JP 7692366B2
Authority
JP
Japan
Prior art keywords
weight
pharmaceutical composition
polyoxyl
methylnaltrexone
glyceride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021565869A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022531685A (ja
JP2022531685A5 (enExample
Inventor
ロバート ロールス，ブライアン
ジェイソン スタイン，ダニエル
クマール，ヴィジェイ
フィリップス，エリック
Original Assignee
バウシュ ヘルス アイルランド リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バウシュ ヘルス アイルランド リミテッド filed Critical バウシュ ヘルス アイルランド リミテッド
Publication of JP2022531685A publication Critical patent/JP2022531685A/ja
Publication of JP2022531685A5 publication Critical patent/JP2022531685A5/ja
Application granted granted Critical
Publication of JP7692366B2 publication Critical patent/JP7692366B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2021565869A 2019-05-07 2020-05-07 メチルナルトレキソンの液体経口投与製剤 Active JP7692366B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962844613P 2019-05-07 2019-05-07
US62/844,613 2019-05-07
US202063010528P 2020-04-15 2020-04-15
US63/010,528 2020-04-15
PCT/EP2020/062794 WO2020225395A1 (en) 2019-05-07 2020-05-07 Liquid oral dosage formulations of methylnaltrexone

Publications (3)

Publication Number Publication Date
JP2022531685A JP2022531685A (ja) 2022-07-08
JP2022531685A5 JP2022531685A5 (enExample) 2023-05-15
JP7692366B2 true JP7692366B2 (ja) 2025-06-13

Family

ID=70802839

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021565869A Active JP7692366B2 (ja) 2019-05-07 2020-05-07 メチルナルトレキソンの液体経口投与製剤

Country Status (9)

Country Link
US (1) US20220096461A1 (enExample)
EP (1) EP3965731A1 (enExample)
JP (1) JP7692366B2 (enExample)
CN (1) CN113747882A (enExample)
AU (1) AU2020268767B8 (enExample)
BR (1) BR112021022194A2 (enExample)
CA (1) CA3137488C (enExample)
MX (1) MX2021013488A (enExample)
WO (1) WO2020225395A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
WO2021224138A1 (en) 2020-05-02 2021-11-11 Bausch Health Ireland Limited Methods of reducing mortality risk in subjects suffering from an underlying disease or condition by administration of methylnaltrexone
AU2022248850A1 (en) * 2021-03-27 2023-11-09 TRx Biosciences Limited Compositions having improved bioavailability of therapeutics
WO2025177181A1 (en) * 2024-02-19 2025-08-28 Nanoprime Labs Corp Self-assembling microemulsions carrying nutraceuticals and methods for use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006522817A (ja) 2003-04-08 2006-10-05 プロジェニックス ファーマシューティカルズ，インコーポレーテッド 過敏性腸症候群を処置するための末梢オピオイドアンタゴニスト、特にメチルナルトレキソンの使用
JP2006522819A (ja) 2003-04-08 2006-10-05 プロジェニックス ファーマシューティカルズ，インコーポレーテッド 緩下薬および末梢オピオイドアンタゴニストを組み合わせた便秘の組み合わせ療法
JP2011190259A (ja) 2010-03-11 2011-09-29 Wyeth Llc メチルナルトレキソンの経口製剤および親油性塩
US20140057934A1 (en) 2012-08-22 2014-02-27 Aptapharma Inc. Methylnaltrexone nasal formulations, methods of making, and use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518433A (en) 1982-11-08 1985-05-21 Fmc Corporation Enteric coating for pharmaceutical dosage forms
US4719215A (en) 1986-03-07 1988-01-12 University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US4861781A (en) 1986-03-07 1989-08-29 The University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US4816259A (en) 1987-02-12 1989-03-28 Chase Chemical Company, L.P. Process for coating gelatin capsules
US5102887A (en) 1989-02-17 1992-04-07 Arch Development Corporation Method for reducing emesis and nausea induced by the administration of an emesis causing agent
US5330759A (en) 1992-08-26 1994-07-19 Sterling Winthrop Inc. Enteric coated soft capsules and method of preparation thereof
DE19651551C2 (de) 1996-12-11 2000-02-03 Klinge Co Chem Pharm Fab Opioidantagonisthaltige galenische Formulierung
US5972954A (en) 1997-11-03 1999-10-26 Arch Development Corporation Use of methylnaltrexone and related compounds
US6559158B1 (en) 1997-11-03 2003-05-06 Ur Labs, Inc. Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
US6274591B1 (en) 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
CN1688294A (zh) 2002-10-01 2005-10-26 旗帜药物胶囊公司 用于制备软胶囊壁的肠溶组合物
US8946262B2 (en) 2003-12-04 2015-02-03 Adolor Corporation Methods of preventing and treating gastrointestinal dysfunction
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
JP6397813B2 (ja) 2012-05-02 2018-09-26 キャプシュゲル・ベルジウム・エヌ・ヴィ ヒドロキシプロピルメチルセルロースアセテートスクシネート（ｈｐｍｃａｓ）の水性分散液
EP3206491B1 (en) * 2014-10-17 2019-11-27 Salix Pharmaceuticals, Inc. Use of methylnaltrexone to attenuate tumor progression

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006522817A (ja) 2003-04-08 2006-10-05 プロジェニックス ファーマシューティカルズ，インコーポレーテッド 過敏性腸症候群を処置するための末梢オピオイドアンタゴニスト、特にメチルナルトレキソンの使用
JP2006522819A (ja) 2003-04-08 2006-10-05 プロジェニックス ファーマシューティカルズ，インコーポレーテッド 緩下薬および末梢オピオイドアンタゴニストを組み合わせた便秘の組み合わせ療法
JP2011190259A (ja) 2010-03-11 2011-09-29 Wyeth Llc メチルナルトレキソンの経口製剤および親油性塩
US20140057934A1 (en) 2012-08-22 2014-02-27 Aptapharma Inc. Methylnaltrexone nasal formulations, methods of making, and use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Letters in Drug Design & Discovery，2011年，Vol.8，pp.87-92

Also Published As

Publication number Publication date
AU2020268767B1 (en) 2025-07-17
CA3137488C (en) 2023-10-31
CN113747882A (zh) 2021-12-03
WO2020225395A1 (en) 2020-11-12
AU2020268767A1 (en) 2021-10-28
MX2021013488A (es) 2021-12-10
AU2020268767B8 (en) 2025-08-07
JP2022531685A (ja) 2022-07-08
BR112021022194A2 (pt) 2021-12-28
EP3965731A1 (en) 2022-03-16
CA3137488A1 (en) 2020-11-12
US20220096461A1 (en) 2022-03-31

Similar Documents

Publication Publication Date Title
US20220096461A1 (en) Liquid oral dosage formulations of methylnaltrexone
JP6820117B2 (ja) 乱用防止カプセル
KR20010093281A (ko) 자발분산성 ｎ-벤조일-스타우로스포린 조성물
KR102771577B1 (ko) 3α-에티닐-3β-하이드록시안드로스탄-17-온 옥심의 약학적 제형
DK2683381T3 (en) Formulation comprising phenylaminopyrimidine derivative as active substance
JP2022531685A5 (enExample)
KR101928589B1 (ko) 알리스포리비르를 포함하는 제약 조성물
RU2827066C2 (ru) Композиции жидкой пероральной лекарственной формы метилналтрексона
CN103181913B (zh) 一种胡椒碱自乳化软胶囊及其制备方法
CN101103962A (zh) 长春西汀口服自微乳化释药系统及其制备方法
RU2397759C2 (ru) Микроэмульсионные композиции, включающие антагонисты вещества р
RU2779262C2 (ru) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ 3α-ЭТИНИЛ-3β-ГИДРОКСИАНДРОСТАН-17-ОНА ОКСИМА
JP2010513351A (ja) 酸を含むゼラチンカプセル剤
CN1771949B (zh) 尼莫地平软胶囊及其制备方法
CN119677509A (zh) 用于治疗炎症和神经炎症的贝特类组合物
KR20070018003A (ko) 특정 물질 ｐ 길항제를 포함하는 마이크로에멀젼 제제
CZ464299A3 (cs) Želatinové zapouzdření roztokové dávkovači formy sertralinu

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220117

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20220117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230502

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230502

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240319

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240326

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240624

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250116

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250527

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250603

R150 Certificate of patent or registration of utility model

Ref document number: 7692366

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150